Pharmacies 36.6

Performance indicators

2023: Revenue growth by 13% to 74.9 billion rubles

According to the results of 2023, the pharmacy chain 36.6 earned revenue of 74.9 billion rubles, which is 13% more than revenue in 2022. This is stated in the financial statements under IFRS, which the company disclosed in early April 2024.

As they write Sheets"" with reference to the materials of the network, comparable sales (revenue of pharmacies operating in the network during the reporting period) "36.6" increased by 2.1%. As explained in the company, the growth of comparable revenue occurred against the background of an increase in the average check by 2.6% and a decrease in traffic by 0.5%. the total number of pharmacies increased by 18.6% to 2,151. The pharmacy chain opened 198 outlets, and 188 pharmacies were also acquired as part of transactions. M&A The indicator EBITDA in 2023 reached 4.6 billion rubles, EBITDA margin - 6.9%.

Unsplash

Revenue of the online sales division in 2023 increased by 29.3% due to an increase in traffic on sites and in the mobile application and amounted to 13.3 billion rubles. The share of online revenue increased to 17.7% of the group's total revenue for 2023.

According to the analytical company DSM Group, in terms of revenue in 2023, the chain ranked seventh among Russian pharmaceutical retailers. At the end of 2023, 36.6 took 4% of the Russian market for drugs sold in pharmacies, and 4.5% in the non-drug market (statistics from the research company RNC Pharma).

In 2023, the 36.6 network received a BBB + (RU) credit rating with a stable forecast from the ACRA rating agency. This made it possible to include corporate bonds in the second quotation list of the Moscow Exchange, the retailer noted.

The long-term obligations of Pharmacy Chain 36.6, according to RAS reports, reached 30 billion rubles in 2023. Short-term liabilities are 1.42 billion rubles, which is 87% more than in 2022.^[1]

2022: Revenue growth by 26.5% to 67.3 billion rubles

The revenue of the pharmacy chain "36.6" in 2022 rose by 26.5% compared to 2021 and reached 67.3 billion rubles. The company operating under the brands "Pharmacy 36.6" and "Gorzdrav" published such data in February 2023.

According to the company, sales increased reporting due to a 15.2% increase in comparable sales and an 11.3% increase in the number of outlets. The increase in comparable revenue occurred against the background of an increase in the average check by 15.2% while maintaining traffic at the level of 2021. The group's revenue from sales through the site and mobile application increased by 170.6% to 10.3 billion rubles. The loan portfolio "36.6" decreased by 12% in 2022, its size is also not indicated.

Revenue of the pharmacy chain "36.6" for the year rose by 26.5%

The share of online destinations has also grown, according to "36.6." Due to increased traffic on sites and in mobile applications, the segment rose to 15.2% of the total network revenue (an increase of 170.6% compared to 2021).

Positive figures in the company are also associated, among other things, with the growth of the number of outlets. The group's total number of pharmacies was 1,814 pharmacies (+ 12.3% yoy). In 2022, the pharmacy chain opened 218 pharmacies, and 33 pharmacies were also acquired as part of transactions M&A.

The absolute value of EBITDA in 2022 increased by 3.2 billion rubles compared to 2021, and profitability increased to 7.1%. Thanks to revenue growth and optimization of business processes, the company recorded a positive net profit in 2022, the report says.

The federal pharmacy chain ended 2022 with a "positive" net profit, the size of which was not disclosed. In 2021, net profit was also not indicated in "36.6^[2]

2021: Revenue growth by 12.1%, to 53.04 billion rubles

At the end of 2021, the 36.6 pharmacy chain raised 53.04 billion rubles, which is 12.1% more than a year earlier. The group announced its financial and operating results on February 10, 2022.

In 2020, the group reported 60 billion rubles of revenue, but this indicator took into account revenue from wholesale sales, and the group's wholesale division was sold at the end of 2020 to the former general director of 36.6 Vladimir Nesterenko.

Revenue from online sales of the network in 2021 increased by 27% due to an increase in traffic on sites and mobile applications and amounted to 3.8 billion rubles. Comparable (LFL) sales growth in 2021 was 6.7%, the number of trading kidneys increased by 10.5%.

Pharmacy chain "36.6" increased annual revenue by 12.1%

In 2021, the chain opened 190 pharmacies in the format "36.6" and "Gorzdrav." As a result of the ongoing campaign to improve operational efficiency, 70 pharmacy outlets were closed. Also, 34 pharmacies were acquired as part of the M&A deal, the company said.

By the end of 2021, the group had 1,616 stores, which is 10.5% more than a year earlier, and their total trading area increased by 4%, to 80 thousand square meters. m.

In 2021, the number of participants in the loyalty program at the 36.6 pharmacy chain increased by 29% compared to a year ago and reached 8 million customers, and the share of purchases with a loyalty card increased by 5 percentage points. up to 66%. Products of own brands and exclusive positions by the end of 2021 accounted for 8% of sales against 4.8% a year earlier.

Data are also provided, according to which the group reduced the total loan portfolio from 40.2 billion rubles as of December 31, 2020 to 21.6 billion rubles a year later. In January 2021, loans from APTEKA-A.V.E. LLC in the amount of 10.0 billion rubles were repaid. During the first half of 2021, exchange-traded bonds of the first issue of the 001P-01 series were purchased in the total amount of 8.6 billion rubles.^[3]

History

2023

36.6 was bought by LekOptTorg & Health Spring

In September 2023, it became known about the sale of the LekOptTorg & Health Support pharmacy chain to the 36.6 group. The company did not disclose the financial terms of the transaction. Read more here.

Purchase of Pharmacon network

On September 1, 2023, it became known about the sale of the Pharmacon company, which operates 18 pharmacies in Ramenskoye (Moscow Region). It was bought by one of the largest Russian pharmacy chains - "36.6" (brands "36.6" and "Gorzdrav"). Its participants did not disclose the financial terms of the agreement. A representative of the 36.6 group, in a conversation with Vedomosti, only said that the deal was held "in a non-standard format for the market - the seller assigned the rights to lease premises." Read more here.

2022: Kit-Pharma Purchase

In early September 2022, it became known about the sale of Keith Pharma the "pharmacy chain 36,6." 29 pharmacies entered the deal perimeter. General Director DSM Group Sergei Shulyak estimates the value of the transaction at 150-180 million. rubles More. here

2021: Purchase of pharmacy chain "36.6 Health"

At the end of November 2021, it became known about the sale of 100% of the Tver network of pharmacies "36.6 Health" to the company "Pharmacy network 36.6" (brands "36.6" and "Gorzdrav"). According to the Unified State Register of Legal Entities, Apteka-A.V.E. LLC (manages 36.6 pharmacies in Moscow) and Apteka-A.V.E.-1 LLC (manages 36.6 pharmacies in the Moscow Region and Kaluga Region) became co-owners of 50% of 36.6 Health LLC. Read more here.

2020

Revenue growth by 16.7%, up to 60 billion rubles

At the end of 2020, Pharmacy Chain 36.6 received revenue of 60 billion rubles, which is 16.7% more than a year earlier. The company's net retail revenue with VAT during this time rose by 9.5% and reached 47 billion rubles. One of the catalysts for the financial rise of the company was the COVID-19 pandemic, because of which Russians tried to buy medicines for future use.

This result was achieved due to: growth in comparable (LFL) sales by 6.5%; an increase in the number of outlets by 4.3% (contribution to revenue growth + 3.1%), the network explained. The growth of comparable revenue (LFL) occurred against the background of an increase in the average check by 12.3% while traffic decreased by -5.2%.

In 2020, Pharmacy Chain 36.6 opened 124 new pharmacies, including 88 outlets in Moscow and the Moscow region. The total number of pharmacies reached 1,460.

In 2020, the pharmacy chain "36.6" increased revenue by 17%

The company's average check growth in 2020 was 12.3%, while traffic decreased by 5.2%. At the same time, the average check for the top 500 pharmacy chains in 2020 increased by 27% and amounted to 642 rubles (data from RNC Pharma).

The key events that influenced the financial indicators in "36.6" are called the COVID-19 pandemic, the transition to competitive purchases through the electronic platform, the increase in the number of loyalty card holders and the sale of the distribution division of "Ji Di Pi."

One of the directions due to which the revenue of the Pharmacy Network 36.6 increased, experts interviewed by Kommersant consider e-commerce. According to the head of Internet projects of the pharmacy chain Tatyana Konchagina, by February 2021, you can book online goods at 1.4 thousand points of the network.

And before remote trading, there was the possibility of booking drugs at the pharmacy. This is a more popular option for buyers who need over-the-counter (OTS) and prescription drugs (Rx), and the remote sale of the latter has not yet been allowed, "said DSM Group CEO Sergei Shulyak.[4]

Sale of GD Distribution Business

In mid-December 2020, the 36.6 pharmacy chain announced the sale of its distribution business. We are talking about the Ji Di Pi division, which was bought by the former CEO of the company Vladimir Nesterenko. Read more here.

Alexander Kuzin - the new general director of the Pharmacy Chain 36.6

In October 2020, Alexander Kuzin headed PJSC Pharmacy Chain 36.6 instead of Vladimir Nesterenko. The corresponding decision was made by the company's board of directors on October 22, and the official change of CEO took place the next day. Read more here.

2015

CROC filed a lawsuit against the Pharmacy Chain 36.6 for 4.87 million rubles.

On March 16, 2015, it became known about the decision of the Moscow Arbitration Court - to recognize as justified the claim of the system integrator "CROC" (CJSC "CROC the Inc.") regarding the determination of the management company "Pharmacy network 36.6"^[5]

'Pharmacy 36.6, 2013'

The court decided to introduce a monitoring procedure for the pharmacy company. The demand of "CROC" to recover 4.872 million rubles from the "Pharmacy Chain 36.6." Included in the third stage of the register of claims of creditors of the debtor. Kirill Smolyaninov was approved as the interim manager of the Criminal Code.

"CROC" went to court at the end of January 2015. In addition, at the end of January, the court registered the application of the Voronezh manufacturer of hematogen "Renaissance and Development" to declare CJSC "Pharmacy 36.6" bankrupt. The bankruptcy application will be considered on April 6, 2015. Earlier, the court satisfied the company's claim to recover a debt of 608.6 thousand rubles from Aptek 36.6. and penalties in the amount of 152.4 thousand rubles.

In mid-February, the court received a statement from A1 Card to declare Pharmacy 36.6 bankrupt. The company's application was adjourned pending earlier applications.

Merger procedure with A.v.e Group

As of March 16, 2015, Pharmacy Chain 36.6 is merging with A.v.e Group (Apteka-A.v.e LLC, Apteka-A.v.e-1 LLC), which will enter the authorized capital of 36.6 as a result of an additional issue, part of which is planned to be paid for by contributing a share of A.v.e. The remainder will be offered for free acquisition to current 36.6 shareholders and other investors. The additional issue is scheduled to be completed by May 2015.

2014

Closing the bankruptcy case after repayment of debt to Istok

In October 2014, the court terminated proceedings at the request of Istok to declare Pharmacy 36.6 CJSC bankrupt due to the repayment by the pharmacy company of debt in the amount of 3.708 million rubles.

Loss in the first half of the year 382 million rubles

According to the results of the first half of 2014, the net loss of Pharmacy Chain PJSC 36.6 amounted to 382 million rubles, having decreased three times compared to the same indicator in 2014.

2012: Artem Bektemirov and Sergey Krivosheev own more than 51% of the company's shares

Artem Bektemirov and Sergey Krivosheev directly own 4.37% of the company's shares, another 47.57% they own in equal shares through Cyprus 36.6 Investments Ltd. In free circulation - 40% (RTS assessment). Pharmacy Chain 36.6 is a public company whose shares are traded on Russian stock exchanges RTS and MICEX (ticker APTK).. Capitalization of the company (MICEX) as of February 12, 2011 - $365 million.

Chairman of the Board of Directors - Sergey Krivosheev, General Director of the parent enterprise of the group (OJSC Pharmacy Network 36.6) - Artem Bektemirov, General Director of the management company - Valeria Solok (since September 15, 2009).

2011:990 points of sale

At the end of the first quarter of 2011, the pharmacy chain consisted of 990 outlets.

2010

Turnover 20.3 billion rubles

Consolidated sales for 2010 amounted to RUR 20,381 million

As of April 1, 2010, the company managed 1004 pharmacies in 29 regions of the Russian Federation, 11 stores of developmental toys for children "Early Development Center - Early Learning Center (ELC)" (joint venture on a parity basis with the British company), 14 optics stores, as well as 21 optics departments located inside pharmacies. In 2010, 45 pharmacies closed and 15 opened.

25% of the company sold to SIA International

In early 2010, it was announced that a 25% stake in the company was sold to SIA International, a large Russian wholesaler of medicines.

2009: Closing of unprofitable points

At the beginning of 2009, 36.6 had 1,084 pharmacies. In the same year, the company began to get rid of unprofitable points. In 2009, 131 pharmacies were closed, and only 23 were opened.

As of March 2009, OJSC Pharmacy Chain 36.6 also controlled 51.8% of the shares of the pharmaceutical company Veropharm, which was one of the five largest Russian manufacturers of pharmaceuticals. Veropharm owns three pharmaceutical plants in Belgorod, Voronezh and Pokrov.

2007: Thousand pharmacy opened

During 2007, 26 networks of 293 points were purchased, another 166 were organically opened.

In July 2007, a thousandth pharmacy was opened in Nizhny Novgorod.

2006:18 chains of 352 pharmacies bought and 75 new outlets opened

In January 2006, a deal was completed to acquire the pharmacy chain Pharmacy (Perm Pharmacies) in the Perm Territory.

In total, 18 chains of 352 pharmacies were purchased in 2006 and 75 new outlets were opened.

2005: Buying up regional pharmacy chains

Until 2008, 36.6 actively bought up regional players and opened new points. In 2005, pharmacy chains were acquired in Volgograd (Good Neighbor), Dmitrov (Mega-Style), Novosibirsk (Pharmacy Trading House), Perm (Health Bowl), Samara (Nebolit), St. Petersburg (Orange and Tablet) and Sarov (Doctor Zelenkin).

1991: Establishing a Company

The company was established in 1991.

Notes